Search

Your search keyword '"Zugmaier G"' showing total 224 results

Search Constraints

Start Over You searched for: Author "Zugmaier G" Remove constraint Author: "Zugmaier G"
224 results on '"Zugmaier G"'

Search Results

1. Improved survival and MRD remission with blinatumomab vs. chemotherapy in children with first high-risk relapse B-ALL

2. Improved survival and MRD remission with blinatumomab vs. chemotherapy in children with first high-risk relapse B-ALL

3. Low leukemia burden improves blinatumomab efficacy in patients with relapsed/refractory B-cell acute lymphoblastic leukemia

6. P359: IMPROVED OVERALL SURVIVAL AND MRD CLEARANCE WITH BLINATUMOMAB VS CHEMOTHERAPY AS PRE-TRANSPLANT CONSOLIDATION IN PEDIATRIC HIGH-RISK FIRST-RELAPSE B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALL)

8. Blinatumomab in pediatric relapsed/refractory B-cell acute lymphoblastic leukemia: RIALTO expanded access study final analysis

9. Author Correction: Blinatumomab in pediatric patients with relapsed/refractory acute lymphoblastic leukemia: results of the RIALTO trial, an expanded access study (Blood Cancer Journal, (2020), 10, 7, (77), 10.1038/s41408-020-00342-x)

10. Long-term survival of patients with relapsed/refractory acute lymphoblastic leukemia treated with blinatumomab

13. CD19 expression in pediatric patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia pre- and post-treatment with blinatumomab

16. Blinatumomab vs historic standard-of-care treatment for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukaemia

17. Blinatumomab versus historical standard therapy in pediatric patients with relapsed/refractory Ph-negative B-cell precursor acute lymphoblastic leukemia

18. Blinatumomab in pediatric patients with relapsed/refractory acute lymphoblastic leukemia: results of the RIALTO trial, an expanded access study

23. Blinatumomab (Anti-CD19 BiTE®) for targeted therapy of minimal residual disease (MRD) in patients with B precursor acute lymphoblastic leukemia (ALL): Update of an ongoing phase II study: V341

25. Abstract

27. Phase I/Phase II study of blinatumomab in pediatric patients with relapsed/refractory acute lymphoblastic leukemia

28. S1619 BLINATUMOMAB FOR MINIMAL RESIDUAL DISEASE (MRD) IN ADULTS WITH BCELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (BCPALL): MEDIAN OVERALL SURVIVAL (OS) NOT REACHED AT 5 YEARS FOR COMPLETE MRD RESPONDERS

29. S825 EVALUATION OF AMG 420, AN ANTI‐BCMA BISPECIFIC T‐CELL ENGAGER (BITE®) IMMUNOTHERAPY, IN R/R MULTIPLE MYELOMA (MM) PATIENTS: UPDATED RESULTS OF A FIRST‐IN‐HUMAN (FIH) PHASE 1 DOSE ESCALATION STUDY

31. Survival after blinatumomab treatment in pediatric patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia

33. Phase I/Phase II study of blinatumomab in pediatric patients with relapsed/refractory acute lymphoblastic leukemia

36. Blockade of the PD-1/PD-L1 axis augments lysis of AML cells by the CD33/CD3 BiTE antibody construct AMG 330: reversing a T-cell-induced immune escape mechanism

38. Long-term follow-up of serum immunoglobulin levels in blinatumomab-treated patients with minimal residual disease-positive B-precursor acute lymphoblastic leukemia

39. Pediatric posttransplant relapsed/refractory B-precursor acute lymphoblastic leukemia shows durable remission by therapy with the T-cell engaging bispecific antibody blinatumomab

41. A phase Ib study of pertuzumab, a recombinant humanised antibody to HER2, and docetaxel in patients with advanced solid tumours

48. The Bi-Specific T-Cell Enhancer (BiTE) MT103 (MEDI-538) Induces Clinical Responses in Heavily Pre-Treated NHL Patients: Update from the Ongoing Phase I Study MT103-104.

Catalog

Books, media, physical & digital resources